NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP-1 Weight Loss Drugs Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC A year ago, the National Consumers League took the unusual step of flagging warnings from the Food and Drug Administration (FDA) and medical societies stating that compounded versions of GLP-1 (glucagon-like peptide-1 receptor agonists) weight-loss drugs are not FDA approved and may cause serious health problems
Committee recommends four peptide nominations despite limited clinical evidence On the first day of the meeting, the committee reviewed BPC-157, KPV, TB-500, and MOTS-c, which have been nominated for compounding for proposed uses including wound healing, inflammatory disorders, metabolic conditions, and osteoporosis
Erlandson, 21 April 2026, npj Aging
Garg BJ, Saraswat A, Bhatia A, Katare OP
Last updated: 31/10/2025 HOW ITS COMPONENTS WORK: A strong antioxidant and detoxifying preparation consisting of L-glutathione reduced (GSH), N-acetylcysteine, grape extract, D-alpha tocopheryl acetate (vitamin E) and L-lysine
T3 and T4 are converted into sulfated forms in the liver and the intestinal tract